Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Post hoc analyses of the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6) showed an increased risk of diabetic retinopathy complications associated with semaglutide versus placebo among patients with a history of retinopathy, especially among those with insulin use (1). Although concerns have been raised regarding the safety of glucagon-like peptide 1 (GLP-1) receptor agonists in patients with existing retinopathy, subgroup analyses by retinopathy status at baseline have not been presented for other trials of GLP-1 receptor agonists; the two observational studies on GLP-1 receptor agonists and diabetic retinopathy performed to date have excluded patients with a history of retinopathy (2) or treatment of retinopathy (3).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy
Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L. (2018) · Diabetes Care · doi:10.2337/dc17-2280 · Cited by 70 · cited 1×
“studies on GLP-1 receptor agonists and diabetic retinopathy performed to date have excludedpatientswithahistoryof retinopathy (2) or treatment of retinopathy (3).”
Background
Cited by
Zheng, D., Li, N., Hou, R., Zhang, X., Wu, L., Sundquist, J., Sundquist, K., & Ji, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02753-6 · Cited by 74
Wai, K. M., Mishra, K., Koo, E., Ludwig, C. A., Parikh, R., Mruthyunjaya, P., & Rahimy, E. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.04.010 · Cited by 61
Yen, F.-S., Wei, J. C.-C., Shih, Y.-H., Hung, Y.-T., Hsu, T.-J., Hsu, C.-C., & Hwu, C.-M. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103099 · Cited by 13
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3
Metadata
- Authors
- Ueda, P., Pasternak, B., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Melbye, M., & Svanström, H.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-04-22
- Volume
- 42
- Issue
- 6
- Pages
- e92-e94
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2938328666
- Cited by
- 24
- References
- 1
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries. https://app.cochat.ai/papers/10.2337/dc18-2532
- The paper
- Ueda, P., Pasternak, B., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Melbye, M., & Svanström, H. (2019). Glucagon-Like Peptide 1 Receptor Agonists and Risk of Diabetic Retinopathy Complications: Cohort Study in Nationwide Registers From Two Countries. Diabetes Care. https://doi.org/10.2337/dc18-2532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.